glp 1 and autoimmune hepatitis Frontiers Glucagon-like peptide-1 receptor agonists improve

The CDC advises that caregivers who have had close contact with a confirmed case or someone under investigation for COVID-19 should closely monitor their own health

GLP-1based therapies share several common adverse effects and carry some rare but important risks

Because it is a demonstration program, CMS may change, extend, or end the program in the future

Using doses below the therapeutic threshold may provide insufficient metabolic benefit, essentially exposing patients to medication risks without meaningful clinical gain

Starting a GLP-1 taught me that struggling with weight is not a character flaw and obesity is not a choice